Lupin Limited

“Lupin is a mid-tier Indian generics company in genuine margin recovery, anchored by a durable India branded franchise and an emerging US inhalation pipeline that represents a real but unproven technical moat. At 23x trailing earnings near the 52-week high, the market has priced the recovery but not the remaining execution risk — a management team with a demonstrably poor capital allocation track record, an unresolved DOJ subpoena, and an FDA enforcement scenario that could cause permanent impairment. The base-case 10-year return of 2.5–3x is adequate but not compelling; the risk-reward only becomes attractive at 15–18x forward earnings, roughly 20–30% lower than current levels.”